Fenofibrate: altered renal function.
In patients with type 2 diabetes, a subgroup analysis of a placebo-controlled trial of fenofibrate showed a significant decline in calculated creatinine clearance with fenofibrate. Most fibrates seem to have a detrimental effect on renal function, with the probable exception of gemfibrozil, which is the fibrate of choice in the few situations in which a fibrate is needed.